Study Reveals Fullerenol Nanoparticles Induce Calreticulin Exposure to Trigger Robust Anti-tumor Immunity
Prof. XING Gengmei's research team from the Institute of High Energy Physics of the Chinese Academy of Sciences recently reported that fullerenol nanoparticles could be used as a safe calreticulin (CRT) exposure inducer to boost the anti-tumor immune efficiency of anti-CD47 monoclonal antibodies (mAbs). The study, entitled “Fullerenols boosting the therapeutic effect of anti-CD47 antibody to trigger robust anti-tumor immunity by inducing calreticulin exposure,”was published in Nano Today.
Feb 01, 2021